GLP-1 medications for menopause-related weight gain: what to know

If you have eaten and moved the same way for years and the scale still crept up somewhere around your late forties, you are not imagining it, and it is not a willpower problem. The menopause transition genuinely changes how the body stores fat and holds onto muscle. GLP-1 medications have become the most-searched answer to that change, but the honest picture is more nuanced than the headlines. This guide explains what actually shifts through menopause, what these medications do and do not do, what the weight-loss evidence shows, where the menopause-specific data is thin, and how to think about the option with a licensed provider rather than a marketing funnel.

Does menopause actually cause weight gain?

Menopause is better understood as a change in where weight sits and what it is made of than as a cause of large weight gain on its own. Most of the steady weight increase women see in midlife tracks with aging rather than with the hormonal transition itself. As one review of body-composition research at menopause puts it, “cross-sectional and longitudinal studies have suggested that the steady gain of weight of approximately 0.5 kg per year is largely related to age rather than menopause” (Weight, Shape, and Body Composition Changes at Menopause, review, PMC).

What the transition does change is the composition of the body. The same review notes that “women in the menopause transition experience significant changes in metabolic and body composition indices with a reduction in fat free mass, and an increase in fat mass,” and that “waist circumference increases significantly over the transition” across ethnic groups (review, PMC). The large longitudinal Study of Women’s Health Across the Nation (SWAN) measured this directly with DXA scans: at the start of the menopause transition (MT), “rate of fat gain doubled, and lean mass declined; gains and losses continued until 2 years after the FMP”, the final menstrual period (Greendale et al., SWAN, JCI Insight 2019, PMC). In that cohort, mean fat gain rose from about 0.25 kg per year before the transition to 0.45 kg per year during it, while lean mass moved from a slight annual gain to a decline of roughly 0.06 kg per year (SWAN, PMC).

Here is the counterintuitive part that explains why so many women feel their bodies changed even when the scale barely moved: because fat is rising while muscle is falling, the total number can stay nearly flat. The SWAN authors found “no discernable change in rate of weight gain at the start of the MT,” and the menopause review reaches the same conclusion, “it may be these opposing changes that result in weight changing very little in response to menopause itself” (SWAN, PMC; review, PMC). The mirror and the waistband register the shift even when the scale does not.

Why fat shifts to the middle during the menopause transition

Fat migrates toward the abdomen during menopause largely because falling estrogen changes where the body deposits fat and how much energy it burns. In the SWAN Fat Patterning Study, visceral fat, the metabolically active fat around the organs, “increased significantly from 3-4 years prior to menopause compared with menopause onset,” then plateaued in the first two postmenopausal years, and only women who actually became postmenopausal showed that significant visceral-fat rise (Lovejoy et al., 2008, Int J Obes, PMC). Over the same window, circulating estradiol fell.

Energy expenditure drops at the same time. In that study, the decline in sleeping energy expenditure “was 1.5-fold greater in women who became postmenopausal compared with premenopausal controls (-7.9 vs -5.3%),” and “fat oxidation decreased by 32% in women who became postmenopausal” while premenopausal women showed no significant change (Lovejoy et al., 2008, PMC). In plainer terms: the body burns a little less at rest and shifts toward storing rather than burning fat, and it parks more of that fat centrally. That central, visceral pattern is not just cosmetic, it is the fat depot most tied to insulin resistance and cardiovascular risk, which is why midlife weight often feels different and more stubborn than weight gained at 25.

None of this means the change is unstoppable or that a medication is required. It means the target that matters is body composition and central fat, not only the scale, and that framing shapes how to read the GLP-1 evidence below.

What GLP-1 medications are and how they work

GLP-1 medications are prescription drugs that mimic a gut hormone the body releases after eating, which reduces appetite and slows stomach emptying so you feel full sooner and longer. The class name comes from that hormone, glucagon-like peptide-1. Its FDA label describes the mechanism plainly: semaglutide “acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1” (Wegovy Prescribing Information, DailyMed). Tirzepatide goes one step further, activating two incretin receptors (GIP and GLP-1) rather than one (Zepbound Prescribing Information, DailyMed).

Two molecules carry FDA approval for chronic weight management, and each is sold under separate brand names for weight and for diabetes, which is a frequent source of confusion. Semaglutide is Wegovy for weight management. Tirzepatide is Zepbound for weight management. Wegovy is indicated, per its label, “in combination with a reduced calorie diet and increased physical activity” to “reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity; Adults with overweight in the presence of at least one weight-related comorbid condition” (Wegovy label, DailyMed). Zepbound carries a comparable weight-management indication and is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound label, DailyMed).

For weight management specifically, Wegovy and Zepbound are the on-label choices. Ozempic and Mounjaro contain the same molecules but are approved for type 2 diabetes; using them for weight loss is an off-label decision a prescriber is responsible for explaining. In March 2026 the FDA approved a higher-dose semaglutide, Wegovy HD (7.2 mg), now the highest-dose semaglutide injection cleared for weight management (FDA, higher-dose semaglutide approval).

How much weight do people lose on GLP-1 medications?

GLP-1 medications produce substantial average weight loss in their pivotal trials, well beyond what diet and activity typically achieve alone. In STEP 1, the pivotal semaglutide weight-management trial, 1,961 adults saw a mean change in body weight of “-14.9% in the semaglutide group as compared with -2.4% with placebo” over 68 weeks (Wilding et al., STEP 1, NEJM 2021, PubMed). In the first head-to-head trial of the two drugs, SURMOUNT-5, tirzepatide reduced body weight by a mean of 20.2% versus 13.7% for semaglutide over 72 weeks, a statistically significant difference (p < 0.001) (SURMOUNT-5, summary via the American College of Cardiology).

Two honest caveats belong next to those numbers. First, averages hide wide individual variation: some people respond strongly to one medicine and modestly to the other, and tolerability differs from person to person. Second, and this matters for anyone reading as a woman in midlife, these landmark trials enrolled adults of both sexes and were not designed to isolate the effect in menopausal women. They tell you the drugs work for weight loss broadly; they were not built to answer “how well does this work specifically for menopause-related weight change?” That question is where the evidence thins out.

What does the evidence show specifically in menopausal women?

Menopause-specific GLP-1 evidence is limited and comes mostly from retrospective, real-world data rather than trials built to answer the menopause question directly. The most-cited menopause-specific signal to date is a Mayo Clinic analysis presented at ENDO 2025, which reviewed electronic medical records of 120 postmenopausal women with overweight or obesity treated with tirzepatide for a median of 18 months. Comparing 40 women who were also using menopausal hormone therapy with 80 who were on tirzepatide alone, the hormone-therapy group lost about 17% of body weight on average versus 14% in the tirzepatide-alone group, and 45% of the hormone-therapy users reached at least 20% total weight loss compared with 18% of non-users (Castaneda et al., Mayo Clinic, ENDO 2025 press release, Endocrine Society). The lead researcher, Regina Castaneda, MD, summarized it as: “The combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women” (Endocrine Society).

That is an interesting, biologically plausible finding, preclinical work in rats has suggested estrogen may enhance the appetite-suppressing effect of GLP-1 (Maske et al., 2017, Hormones and Behavior, PMC), but it is important to read it for exactly what it is. It is a retrospective, real-world cohort of 120 women, not a randomized controlled trial. Observational studies of this kind can be shaped by differences between the two groups that have nothing to do with the drugs (for example, women already choosing hormone therapy may differ in ways that also affect weight). Findings like this are hypothesis-generating: they point toward questions worth studying in proper trials, not conclusions to bank on. As of 2026 there is no large randomized trial designed to establish how GLP-1 medications perform specifically in menopausal women, or whether adding hormone therapy causes the extra weight loss the retrospective data hints at.

The practical takeaway is not “menopause makes GLP-1s work better or worse.” It is that the general efficacy evidence is strong, the menopause-specific evidence is early and observational, and the right decision is individual rather than something a webpage can settle.

Can you take a GLP-1 with menopausal hormone therapy (HRT)?

Whether a GLP-1 and menopausal hormone therapy can be used together is an individual medical decision, and the two are separate treatments prescribed for separate reasons. Hormone therapy is prescribed to manage menopausal symptoms and related risks; a GLP-1 is prescribed for weight management. Some women are candidates for one, both, or neither, and that determination belongs to a licensed clinician who knows your full history. The retrospective Mayo data above described women who happened to be on both, and it suggested greater average weight loss in that group (Endocrine Society, ENDO 2025), but it did not prove that combining them causes better results, and it is not a reason to start hormone therapy in order to boost weight loss. Each therapy has its own candidacy criteria, benefits, and risks that a provider weighs on their own merits. If you are considering both, that is a good conversation to have in one visit rather than a decision to make from an article.

Side effects and what matters more at midlife

The most common GLP-1 side effects are gastrointestinal and usually ease as the dose is raised slowly. On the Wegovy label the most common adverse reactions are “nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%)” (Wegovy label, DailyMed). Slow dose titration, hydration, and eating adjustments are the standard ways a provider keeps these manageable, which is one reason clinician oversight matters more than a low price.

Both semaglutide and tirzepatide also carry a boxed warning about thyroid tumors. The Wegovy label states that “in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors,” that it is unknown whether this occurs in humans, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (Wegovy label, DailyMed). That warning is one reason these are prescription medications that call for a real clinical evaluation, not a questionnaire alone.

There is one more consideration that is specific to midlife. Menopause is already a time of accelerating lean-mass loss, recall that in SWAN, lean mass shifts to a decline of about 0.06 kg per year during the transition (SWAN, PMC). Any large, rapid weight loss costs some muscle along with fat, so a woman losing weight during or after menopause has extra reason to protect lean mass and bone: adequate protein, progressive resistance training, and a controlled rate of loss set with a provider. The goal is to lose fat while keeping as much muscle and strength as possible, not simply to move the scale down as fast as possible. For a deeper look at protecting muscle during medication-assisted weight loss, see our companion coverage on growth-hormone peptides and body composition and pair any plan with strength training.

Branded vs compounded GLP-1s, and how online access works

The GLP-1s with the trial data above are the branded medicines, and that is the main thing to know about compounded versions. Pharmacies were allowed to compound semaglutide and tirzepatide during the 2023 to 2024 shortages; the FDA has since determined those shortages resolved and ended the related enforcement-discretion windows (FDA, policies for compounders as GLP-1 supply stabilizes). Compounded versions have not been evaluated or approved by the FDA, and in March 2026 the agency sent warning letters to 30 telehealth companies over misleading marketing of compounded GLP-1 products (FDA warns 30 telehealth companies), so be wary of any program that calls a compounded product the same as the brand.

GLP-1 medications are not controlled substances, so they can be prescribed through telehealth, but the prescriber must be licensed in your state (HHS Telehealth, licensing across state lines). A responsible visit reviews your history, goals, and appropriate labs before a clinician decides whether a GLP-1 fits, and a prescription is never promised in advance. For what the branded drugs cost by channel, PeptideAgent’s Zepbound cost page covers savings cards, self-pay vials and pens, and the Medicare GLP-1 Bridge.

The bottom line

Menopause reshapes the body more than it inflates the scale: fat rises, lean mass falls, and weight shifts toward the abdomen as estrogen declines. GLP-1 medications, branded semaglutide (Wegovy) and tirzepatide (Zepbound), are FDA-approved for chronic weight management and produce large average weight loss in trials, but those trials were not built around menopausal women, and the menopause-specific evidence so far is early, retrospective, and hypothesis-generating rather than settled. That combination argues for neither hype nor dismissal, but for an individualized conversation: a licensed provider who reviews your history, protects your muscle and bone, and decides with you whether a GLP-1 fits, alongside the nutrition and strength work that matters even more at midlife. If you want to keep researching first, see our guides to peptides versus HRT for menopause and peptides for weight loss for women, which sets GLP-1s beside the research compounds women see online, and how online prescribing works.

Sources

Every clinical figure on this page traces to an FDA product label, a peer-reviewed study, or a named institutional source, and every regulatory date to an FDA statement. They are listed here so you can verify each claim directly.

• Greendale GA, et al. Changes in body composition and weight during the menopause transition (SWAN), JCI Insight 2019, PMC, the DXA-measured doubling of fat-gain rate, the shift from lean-mass gain to loss during the transition, and the finding of no acceleration in total weight gain at menopause.
• Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition, Int J Obes 2008, PMC, the significant visceral-fat rise around menopause onset and the greater decline in sleeping energy expenditure and fat oxidation in women who became postmenopausal.
• Weight, Shape, and Body Composition Changes at Menopause (review), PMC, the framing that steady midlife weight gain is largely age-related while the transition changes body composition and fat distribution, with waist circumference rising.
• Wegovy (semaglutide) Prescribing Information, DailyMed, the GLP-1 mechanism of action, the chronic-weight-management indication, the thyroid C-cell tumor boxed warning and contraindication, and the most common adverse reactions.
• Zepbound (tirzepatide) Prescribing Information, DailyMed, the dual GIP and GLP-1 mechanism and the weight-management and obstructive-sleep-apnea indications.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021, PubMed, the −14.9% vs −2.4% mean weight change over 68 weeks in 1,961 adults.
• SURMOUNT-5: tirzepatide vs semaglutide (summary via the American College of Cardiology), the head-to-head 72-week mean weight loss of 20.2% (tirzepatide) versus 13.7% (semaglutide), p < 0.001.
• FDA, approval of higher-dose semaglutide (Wegovy HD, 7.2 mg), the March 2026 approval of the 7.2 mg weight-management dose.
• Castaneda R, et al. Tirzepatide with menopause hormone therapy in postmenopausal women (Mayo Clinic), ENDO 2025, Endocrine Society press release, the retrospective real-world cohort of 120 postmenopausal women, the 17% vs 14% mean weight loss, and the 45% vs 18% who reached at least 20% loss.
• Maske CB, et al. Estradiol modulates the anorexic response to central glucagon-like peptide 1, Hormones and Behavior 2017, PMC, the preclinical (ovariectomized rat) finding that estradiol potentiates the appetite-suppressing response to GLP-1, the basis for the “biologically plausible” note.
• FDA, policies for compounders as national GLP-1 supply stabilizes, the resolution of the shortages and the end of the compounding enforcement-discretion windows.
• FDA, warns 30 telehealth companies against illegal marketing of compounded GLP-1s, the March 2026 enforcement wave against false or misleading compounded-GLP-1 marketing.
• HHS Telehealth, licensing across state lines, the rule that a prescriber must be licensed in the patient’s state, with state medical boards setting their own standards.